Skip to content

Study · Observational study · n = 34 · 2013

8 results

Time to menarche and final height after histrelin implant treatment for central precocious puberty.

Gillis D, Karavani G, Hirsch HJ, Strich D

The Journal of pediatrics26 Feb 2013Cited by 21 (Europe PMC)

PMID23485026 (opens in a new tab)DOI10.1016/j.jpeds.2013.01.021 (opens in a new tab)PepBankPUB-23485026
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, triptorelin was linked to later menarche after treatment than histrelin.

    In plain wordsIn girls with early puberty, triptorelin was linked to later periods after treatment compared with histrelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTime to menarche after treatment
    Study

    n = 34

    Comparator
    histrelin implant
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · 26.7 ± 2.5 monthsAs given in this study (human).

    Measurements

    Time to menarche
    16.1 months
    TD group
    Time to menarche
    9.3 months
    histrelin implant group

    Source sentences

    Summary
    Time between removal of implant or last injection and menarche was 9.3 ± 1.5 (histrelin implant group) versus 16.1 ± 1.7 (TD group) months (P = .02).
    1 context sentence
    Summary · context
    Chart review, interview, and final height measurements of 2 groups of girls with central precocious puberty; triptorelin depot (TD) group: 23 girls were treated from age 8.4 ± 0.3 with monthly injections of TD, for 26.7 ± 2.5 months; histrelin implant group: 11 girls were treated from age 8.7 ± 0.3…
  2. 02HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, BMI-SDS change did not differ significantly between triptorelin and histrelin implant treatment.

    In plain wordsIn girls with early puberty, BMI-SDS changes were similar with triptorelin and histrelin implants.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeBMI-SDS change
    Study

    n = 34

    Comparator
    histrelin implant
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26.7 ± 2.5 monthsAs given in this study (human).

    Measurements

    BMI-SDS change
    −0.03 SDS
    TD
    BMI-SDS change
    −0.41 SDS
    histrelin implant

    Source sentences

    Summary
    Change from onset of treatment to final BMI-SDS for histrelin implant was -0.41 ± 0.3, and for TD was -0.03 ± 0.2 (NS).
    1 context sentence
    Summary · context
    Chart review, interview, and final height measurements of 2 groups of girls with central precocious puberty; triptorelin depot (TD) group: 23 girls were treated from age 8.4 ± 0.3 with monthly injections of TD, for 26.7 ± 2.5 months; histrelin implant group: 11 girls were treated from age 8.7 ± 0.3…
  3. 03HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, final height did not differ between triptorelin and histrelin implant treatment.

    In plain wordsIn girls with early puberty, final height was similar with triptorelin and histrelin implants.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeFinal height between treatments
    Study

    n = 34

    Comparator
    histrelin implant
    Outcome group
    Linear growth · Reproductive and sexual health
    Studied dose
    Dose not stated · 26.7 ± 2.5 monthsAs given in this study (human).

    Measurements

    Final height
    157.9 cm
    TD
    Final height
    161.1 cm
    histrelin implant

    Source sentences

    Summary
    There was no difference in final height or BMI outcomes between the 2 treatment modalities.
    3 context sentences
    Summary · context
    Predicted height at implant insertion was 156.8 ± 2.6 cm, and final height was 161.1 ± 2.0 cm (not significant [NS]).
    Summary · context
    Predicted height for TD was 155.2 ± 1.9 cm and final height was 157.9 ± 1.7 cm (NS).
    Summary · context
    Chart review, interview, and final height measurements of 2 groups of girls with central precocious puberty; triptorelin depot (TD) group: 23 girls were treated from age 8.4 ± 0.3 with monthly injections of TD, for 26.7 ± 2.5 months; histrelin implant group: 11 girls were treated from age 8.7 ± 0.3…
  4. 04HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, final height after triptorelin did not differ significantly from predicted height.

    In plain wordsIn girls with early puberty, final height after triptorelin did not differ significantly from predicted height.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeFinal height versus predicted height
    Study

    n = 23

    Comparator
    predicted height
    Outcome group
    Linear growth · Reproductive and sexual health
    Studied dose
    Dose not stated · 26.7 ± 2.5 monthsAs given in this study (human).

    Measurements

    Predicted height
    155.2 cm
    TD
    Final height
    157.9 cm
    TD

    Source sentences

    Summary
    Predicted height for TD was 155.2 ± 1.9 cm and final height was 157.9 ± 1.7 cm (NS).
    1 context sentence
    Summary · context
    Chart review, interview, and final height measurements of 2 groups of girls with central precocious puberty; triptorelin depot (TD) group: 23 girls were treated from age 8.4 ± 0.3 with monthly injections of TD, for 26.7 ± 2.5 months; histrelin implant group: 11 girls were treated from age 8.7 ± 0.3…
  5. 05HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, final height after histrelin was 161.1 ± 2.0 cm versus predicted 156.8 ± 2.6 cm, without significance.

    In plain wordsIn girls with central precocious puberty, final height after histrelin exceeded predicted height, but the difference was not significant.

    Peptide
    Histrelin
    Outcome
    IncreaseFinal height versus predicted height
    Study

    n = 11

    Comparator
    Predicted height at implant insertion
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · implant · 28.4 ± 3.7 months of treatment; 9 of 11 initially received monthly triptorelin depot injections for 1.5-39 monthsAs given in this study (human).

    Measurements

    Predicted height
    156.8 cm
    implant insertion
    Final height
    161.1 cm
    histrelin implant

    Source sentences

    Summary
    Predicted height at implant insertion was 156.8 ± 2.6 cm, and final height was 161.1 ± 2.0 cm (not significant [NS]).
    1 context sentence
    Summary · context
    histrelin implant group: 11 girls were treated from age 8.7 ± 0.3 years for 28.4 ± 3.7 months, of whom 9 initially received monthly TD injections for 1.5-39 months.
  6. 06HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, menarche occurred 9.3 ± 1.5 months after histrelin removal versus 16.1 ± 1.7 after triptorelin (P = .02).

    In plain wordsIn girls with central precocious puberty, menarche occurred sooner after histrelin removal than after the last triptorelin injection.

    Peptide
    Histrelin
    Outcome
    DecreaseTime to menarche after treatment cessation
    Study

    n: not reported in source

    Comparator
    Triptorelin depot
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · implant · 28.4 ± 3.7 months of treatment; 9 of 11 initially received monthly triptorelin depot injections for 1.5-39 monthsAs given in this study (human).

    Measurements

    Time to menarche
    9.3 months
    histrelin implant
    Time to menarche
    16.1 months
    triptorelin depot

    Source sentences

    Summary
    Time between removal of implant or last injection and menarche was 9.3 ± 1.5 (histrelin implant group) versus 16.1 ± 1.7 (TD group) months (P = .02).
    1 context sentence
    Summary · context
    histrelin implant group: 11 girls were treated from age 8.7 ± 0.3 years for 28.4 ± 3.7 months, of whom 9 initially received monthly TD injections for 1.5-39 months.
  7. 07HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, final height was numerically higher after histrelin than triptorelin, with no reported significant difference between modalities.

    In plain wordsIn girls with central precocious puberty, final height was numerically higher after histrelin than triptorelin, without a significant difference.

    Peptide
    Histrelin
    Outcome
    IncreaseFinal height versus triptorelin depot
    Study

    n: not reported in source

    Comparator
    Triptorelin depot
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · implant · 28.4 ± 3.7 months of treatment; 9 of 11 initially received monthly triptorelin depot injections for 1.5-39 monthsAs given in this study (human).

    Measurements

    Final height
    161.1 cm
    histrelin implant
    Final height
    157.9 cm
    triptorelin depot

    Source sentences

    Summary
    Predicted height at implant insertion was 156.8 ± 2.6 cm, and final height was 161.1 ± 2.0 cm (not significant [NS]).
    3 context sentences
    Summary · context
    Predicted height for TD was 155.2 ± 1.9 cm and final height was 157.9 ± 1.7 cm (NS).
    Summary · context
    There was no difference in final height or BMI outcomes between the 2 treatment modalities.
    Summary · context
    histrelin implant group: 11 girls were treated from age 8.7 ± 0.3 years for 28.4 ± 3.7 months, of whom 9 initially received monthly TD injections for 1.5-39 months.
  8. 08HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, BMI-SDS change was -0.41 ± 0.3 with histrelin versus -0.03 ± 0.2 with triptorelin (NS).

    In plain wordsIn girls with central precocious puberty, BMI-SDS decreased numerically more with histrelin than triptorelin, without a significant difference.

    Peptide
    Histrelin
    Outcome
    DecreaseBMI-SDS change
    Study

    n: not reported in source

    Comparator
    Triptorelin depot
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · implant · 28.4 ± 3.7 months of treatment; 9 of 11 initially received monthly triptorelin depot injections for 1.5-39 monthsAs given in this study (human).

    Measurements

    BMI-SDS change
    −0.41 SDS
    histrelin implant
    BMI-SDS change
    −0.03 SDS
    triptorelin depot

    Source sentences

    Summary
    Change from onset of treatment to final BMI-SDS for histrelin implant was -0.41 ± 0.3, and for TD was -0.03 ± 0.2 (NS).
    1 context sentence
    Summary · context
    histrelin implant group: 11 girls were treated from age 8.7 ± 0.3 years for 28.4 ± 3.7 months, of whom 9 initially received monthly TD injections for 1.5-39 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.